(DPH.L) Dechra Pharmaceuticals PLC Buy/Sell

RNS Number : 6657I
  Dechra Pharmaceuticals PLC
  16 March 2010
   

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 16 March 2010

 Name ofapplicant:                                                     Dechra Pharmaceuticals PLC
 Name of scheme:                                                       Long-Term Incentive Scheme
 Period of return:                                              From:  22 September 2009  To:  14 March 2010
 Balance of unallotted securities under scheme(s) from previous                                          Nil
 return:
 Plus: The amount by which the block scheme(s) has been increased                                    216,128
 since the date of the last return (if any increase has been applied
 for):
 Less: Number ofsecuritiesissued/allotted under scheme(s) during                                     216,128
 period (see LR3.5.7G):
 Equals: Balance under scheme(s) not yet issued/allotted at end of                                       Nil
 period:
                                                                                                            

 Name of contact:              Zoe Goulding
 Telephone number of contact:  01782 771100

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 16 March 2010

 Name ofapplicant:                                                     Dechra Pharmaceuticals PLC
 Name of scheme:                                                       Approved Share Option Scheme
 Period of return:                                              From:  15 September 2009  To:  14 March 2010
 Balance of unallotted securities under scheme(s) from previous                                      233,167
 return:
 Plus: The amount by which the block scheme(s) has been increased                                    120,000
 since the date of the last return (if any increase has been applied
 for):
 Less: Number ofsecuritiesissued/allotted under scheme(s) during                                      57,062
 period (see LR3.5.7G):
 Equals: Balance under scheme(s) not yet issued/allotted at end of                                   296,105
 period:
                                                                                                            

 Name of contact:              Zoe Goulding
 Telephone number of contact:  01782 771100

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 16 March 2010

 Name ofapplicant:                                                     Dechra Pharmaceuticals PLC
 Name of scheme:                                                       Unapproved Share Option Scheme
 Period of return:                                              From:  15 September 2009  To:  14 March 2010
 Balance of unallotted securities under scheme(s) from previous                                      112,000
 return:
 Plus: The amount by which the block scheme(s) has been increased                                        Nil
 since the date of the last return (if any increase has been applied
 for):
 Less: Number ofsecuritiesissued/allotted under scheme(s) during                                      13,938
 period (see LR3.5.7G):
 Equals: Balance under scheme(s) not yet issued/allotted at end of                                    98,062
 period:
                                                                                                            

 Name of contact:              Zoe Goulding
 Telephone number of contact:  01782 771100

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 16 March 2010

 Name ofapplicant:                                                     Dechra Pharmaceuticals PLC
 Name of scheme:                                                                                 SAYE Scheme
 Period of return:                                              From:  15 September 2009  To:  14 March 2010
 Balance of unallotted securities under scheme(s) from previous                                       30,093
 return:
 Plus: The amount by which the block scheme(s) has been increased                                    190,000
 since the date of the last return (if any increase has been applied
 for):
 Less: Number ofsecuritiesissued/allotted under scheme(s) during                                     158,299
 period (see LR3.5.7G):
 Equals: Balance under scheme(s) not yet issued/allotted at end of                                    61,794
 period:
                                                                                                            

 Name of contact:              Zoe Goulding
 Telephone number of contact:  01782 771100

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
BLRSFUFDMFSSEID

RNS Number : 7781H Dechra Pharmaceuticals PLC 26 February 2010

Dechra Pharmaceuticals PLC

(the "Company")

26 February 2010

In conformity with DTR 5.6.1R, the Company notifies the market of the following:

As at the date of this announcement, the Company's issued share capital consists of 66,028,193 ordinary shares with a nominal value of 1 pence each ("Ordinary Shares"), with voting rights. The Company does not hold any Ordinary Shares in Treasury.

Therefore, the total number of Ordinary Shares with voting rights is 66,028,193.

The above figure of 66,028,193 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

For further information

Zoe Goulding, Company Secretary

Telephone number: 01782 771100

This information is provided by RNS The company news service from the London Stock Exchange

TVREQLFLBLFFBBF

RNS Number : 7732H Dechra Pharmaceuticals PLC 26 February 2010

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer Dechra Pharmaceuticals PLC

of existing shares to which voting rights are attached:ii 2 Reason for the notification(please tick the appropriate box or boxes):
An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify):
3. Full name of person(s) subject to the BlackRock, Inc.

notification obligation:iii 4. Full name of shareholder(s) (if different from 3.):iv
5. Date of the transaction and date on 23rdFebruary 2010

which the threshold is crossed or reached:v
6. Date on which issuer notified: 26thFebruary 2010
7. Threshold(s) that is/are crossed or Holding has gone below 5%

reached:vi, vii

8. Notified details: A: Voting rights attached to sharesviii, ix
Class/type of Situation previous Resulting situation after the triggering transaction
shares to the triggering
transaction

if possible using the ISIN CODE
Number Number Number Number of voting % of voting rightsx
of of of shares rights
Shares Voting
Rights
Direct Directxi Indirectxii Direct Indirect
GB0009633180 3,393,582 3,393,582 N/A N/A 3,086,592 N/A 4.68%

B: Qualifying Financial Instruments Resulting situation after the triggering transaction
Type of financial Expiration Exercise/ Number of voting % of voting
instrument datexiii Conversion Periodxiv rights that may be rights
acquired if the
instrument is
exercised/ converted.

C: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xvi Resulting situation after the triggering transaction
Type of financial Exercise price Expiration datexvii Exercise/ Number of voting rights instrument refers to % of voting rightsxix, xx
instrument Conversion periodxviii
Nominal Delta

Total (A+B+C)
Number of voting rights Percentage of voting rights
3,086,592 4.68%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:xxi BlackRock Investment Management (UK) Limited - 3,086,592 (4.68%)

Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights:

13. Additional information: BlackRock Compliance Disclosures Team
14. Contact name: Stuart Watchorn
15. Contact telephone number: 020 7743 5741; stuart.watchorn@blackrock.com

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation
Full name BlackRock, Inc.

(including legal form of legal entities)
Contact address 33 King William
(registered office for legal entities) Street, London, EC4R

Phone number & email 020 7743 5741;
stuart.watchorn@
blackrock.com
Other useful information Stuart Watchorn

(at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

This information is provided by RNS The company news service from the London Stock Exchange

HOLDMGZZDVGGGZM

RNS Number : 6716H Dechra Pharmaceuticals PLC 25 February 2010

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying Dechra

issuer of existing shares to which voting rights Pharmaceuticals PLC are attached:

2 Reason for the notification(please tick the appropriate box or boxes):
X

An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify):

3. Full name of person(s) subject to the BlackRock, Inc,

notification obligation: 4. Full name of shareholder(s)(if different from 3.):
5. Date of the transaction and date on which the 22ndFebruary 2010

threshold is crossed or reached:
6. Date on which issuer notified: 24thFebruary 2010

7. Threshold(s) that is/are crossed or reached: Holding has gone above 5%

8. Notified details: A: Voting rights attached to shares
Class/type of Situation previous Resulting situation after the triggering transaction
shares to the triggering
transaction

if possible using the ISIN CODE
Number Number Number Number of voting % of voting rights
of of of shares rights
Shares Voting
Rights
Direct Direct Indirect Direct Indirect
GB0009633180 3,276,230 3,276,230 N/A N/A 3,393,582 N/A 5.14%

B: Qualifying Financial Instruments Resulting situation after the triggering transaction
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that may be rights
Period acquired if the
instrument is
exercised/
converted.

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments Resulting situation after the triggering transaction
Type of financial Exercise Expiration Exercise/ Number of voting % of voting rights
instrument price date Conversion rights instrument
period refers to
Nominal Delta

Total (A+B+C) Number of voting rights Percentage of voting rights 3,393,582
5.14%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: BlackRock Investment Management (UK) Limited - 3,393,582 (5.14%)

Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights:

13. Additional information: BlackRock Compliance Disclosures Team
14. Contact name: Stuart Watchorn

15. Contact telephone number: 020 7743 5741; stuart.watchorn@blackrock.com

This information is provided by RNS The company news service from the London Stock Exchange

HOLZMGZZGKZGGZM